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Abstract
CMT4J is a severe form of Charcot-Marie-Tooth neuropathy caused by mutation of the phosphoinositide phosphatase FIG4/
SAC3. Affected individuals are compound heterozygotes carrying the missense allele FIG4-I41T in combination with a null
allele. Analysis using the yeast two-hybrid system demonstrated that the I41T mutation impairs interaction of FIG4 with the
scaffold protein VAC14. The critical role of this interaction was confirmed by the demonstration of loss of FIG4 protein in
VAC14 null mice. We developed a mouse model of CMT4J by expressing a Fig4-I41T cDNA transgene on the Fig4 null
background. Expression of the mutant transcript at a level 56higher than endogenous Fig4 completely rescued lethality,
whereas 26expression gave only partial rescue, providing a model of the human disease. The level of FIG4-I41T protein in
transgenic tissues is only 2% of that predicted by the transcript level, as a consequence of the protein instability caused by
impaired interaction of the mutant protein with VAC14. Analysis of patient fibroblasts demonstrated a comparably low level
of mutant I41T protein. The abundance of FIG4-I41T protein in cultured cells is increased by treatment with the proteasome
inhibitor MG-132. The data demonstrate that FIG4-I41T is a hypomorphic allele encoding a protein that is unstable in vivo.
Expression of FIG4-I41T protein at 10% of normal level is sufficient for long-term survival, suggesting that patients with
CMT4J could be treated by increased production or stabilization of the mutant protein. The transgenic model will be useful
for testing in vivo interventions to increase the abundance of the mutant protein.
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Introduction
The lipid phosphatase FIG4/SAC3 is broadly expressed in
eukaryotic cells from yeast to mammals. Mutations of FIG4 are
responsible for Charcot-Marie-Tooth Disease type 4J (OMIM
611228), an atypical, autosomal recessive form of CMT with severe
motor dysfunction and rapid progression [1,2]. FIG4 phosphatase
activity specifically removes the 5-phosphate from the inositol ring
of PI(3,5)P2, a membrane-bound phospholipid that acts as a
molecular signal fortrafficking and fusion of intracellularvesicles. In
yeast, Fig4p is localized to the vacuole membrane in a protein
complex that regulatesthe synthesisand turnoverofPI(3,5)P2 [3–5].
In mammalian cells, the PI(3,5)P2 biosynthetic complex is localized
in the endosomal/lysosomal vesicle system [6]. Deficiency of
mammalian FIG4 or VAC14 leads to accumulation of cytoplasmic
vacuoles in tissues and in cultured fibroblasts and neurons [1,3,7,8].
We previously identified a spontaneous null mutant of mouse
Fig4 caused by a transposon insertion [1]. The most striking
phenotypes of the Fig4 null mice are spongiform degeneration of
the brain and loss of neurons from the dorsal root ganglia,
resulting in a severe movement disorder and lethality between 1
and 2 months of age (see video supplement to [1]). At the cellular
level, Fig4 null fibroblasts exhibit reduced levels of PI(3,5)P2
[1,9,10]. In the CNS, astrocytes and neurons exhibit accumulation
of p62, ubiquinated protein and other autophagic components in
cytoplasmic inclusion bodies [11]. These abnormalities demon-
strate that PI(3,5)P2 is required for completion of basal autophagy,
and indicate that there is a defect in resolution of autolysosomes in
deficient cells [12].
The biosynthetic complex that regulates PI(3,5)P2 contains two
major proteins in addition to FIG4, the 5-kinase FAB1/PIKfyve,
which phosphorylates position 5 of the inositol ring in PI3P, and
the scaffold protein VAC14, composed of multiple heat-repeat
structural domains [3]. Stable localization on the yeast vacuolar
membrane requires interaction between Fig4p, Fab1p and
Vac14p, and loss of one protein results in mislocalization of the
PLoS Genetics | www.plosgenetics.org 1 June 2011 | Volume 7 | Issue 6 | e1002104other two [3,9]. In the mouse, the phenotype of the spontaneous
Vac14 mutation L156R mimics the Fig4 null phenotype, with
neurodegeneration, cellular vacuolization and defective autophagy
[3,11]. Vac14-L156R is located in a heat repeat domain and the
mutation reduces binding affinity for FAB1, thereby disrupting the
PI(3,5)P2 biosynthetic complex [3]. These mutants in yeast and
mouse demonstrate the importance of the stable complex between
FIG4, FAB1 and VAC14.
Patients with CMT4J are compound heterozygotes at the FIG4
locus, carrying the shared missense mutation I41T, on a common
haplotype, in combination with a unique or ‘‘private’’ null allele
[1]. The frequency of the I41T allele is less than 1/500 in the
Northern European population [1]. The corresponding yeast
mutant, I59T, retains partial function in a yeast assay for
correction of the vacuole phenotype [1,13]. Disease onset in
CMT4J patients with the genotype FIG4
I41T/2 may occur in
childhood or adult life. The rapid decline of motor function in
adult onset patients resembles the course of ALS, and deleterious
mutations of FIG4 have also been identified in patients with ALS
[13]. In order to generate a mouse model of human CMT4J, we
have expressed a Fig4 cDNA construct containing the I41T
mutation in transgenic mice. Here we report the dose-dependent
rescue of the Fig4 null phenotype by the Fig4-I41T transgene. We
also demonstrate that the pathogenic mechanism of the I41T allele
is based on defective interaction with the scaffold protein VAC14,
resulting in destabilization of the FIG4 protein in vivo.
While this work was in progress, Shisheva and colleagues
reported related work indicating that the short half-life of a GFP-
FIG4 fusion protein in cultured cells is increased by over-
expression of myc-VAC14, and that the I41T mutation prevents
this increase [14]. The authors proposed that VAC14 has a novel
regulatory role in the turnover of FIG4 protein [14]. Using the
yeast two hybrid system, we demonstrate here that the direct
interaction between VAC14 and FIG4 is impaired by the I41T
mutation. The reduced interaction results in greatly reduced
abundance of FIG4-I41T protein in patient fibroblasts. We further
demonstrate that wildtype FIG4 requires VAC14 for stability in
vivo. Finally, we find that overexpression of mutant I41T protein
can compensate for its reduced binding affinity and rescue the
mouse model of CMT4J. This work extends the previous
observations and advances our understanding of the pathogenic
mechanism of the FIG4-I41T mutation.
Results
Impaired interaction of FIG4-I41T with the scaffold
protein VAC14
The corresponding yeast mutation, Fig4-I59T, results in
impaired vacuole morphology and defective regulation of
PI(3,5)P2 [1,13]. We tested the interaction of Fig4p-I59T with
the Fig4p binding partners Vac14p and Fab1p using a directed
yeast two hybrid assay. Fig4p was fused to the DNA binding
domain of GAL4 and Vac14p was fused to the transcription
activation domain. The I59T mutant did not support growth
under stringent selection in the presence of 3AT (Figure 1A). This
result demonstrates reduced binding of the Fig4p-I59T mutant to
Vac14p. This result was confirmed in a co-immunoprecipitaton
assay using myc-tagged Fig4p and GFP-tagged Vac14p [15].
Wildtype and mutant yeast proteins were expressed at similar
levels, but co-precipitation of Vac14p was reduced by approxi-
mately 75% for Fig4p-I59T (Figure 1B). Co-immunoprecipitation
of GFP-labeled Fab1p was reduced to a similar extent by the
Fig4p-I59T mutation (Figure 1C). The latter could be an indirect
effect of impaired interaction with Vac14p.
To confirm the effect of the I41T mutation in the context of the
mammalian proteins, we tested the interactions of human FIG4 and
human VAC14 in the yeast two hybrid system. The I41T mutation
significantly impaired theinteractionbetweenthe twohumanproteins,
preventing growth on both of the selective media (Figure 1D). These
experiments demonstrate that the isoleucine-to-threonine substitution
reduces the direct interaction of FIG4 with VAC14.
Interaction with VAC14 is required for stability of
wildtype FIG4 protein in vivo
To investigate the in vivo dependence of FIG4 on interaction
with the VAC14 scaffold protein, we examined FIG4 levels in
tissues from a Vac14 null mouse [7]. The absence of VAC14 in the
null mouse was confirmed by Western blot (Figure 2A). To detect
FIG4 protein we generated a monoclonal antibody to a
bacterially-expressed 220 amino acid fragment from the C-
terminus of FIG4 (Materials and Methods). The monoclonal
antibody recognizes a single protein of ,100 kDa in homogenates
of mouse tissues, consistent with the calculated molecular weight of
103 kDa for the 907 amino acid FIG4 protein (Figure S1).
Remarkably, the abundance of FIG4 protein was greatly reduced
in the Vac14 null mouse (Figure 2B), although the level of Fig4
mRNA was normal (Figure 2C, 2D). Although FIG4 protein was
undetectable in the tissue extract, a very low level of protein could
be detected in cultured fibroblasts by Western blot (Figure S2).
The data demonstrate that wildtype mammalian FIG4 protein is
dependent on interaction with VAC14 for stability.
Generation of Fig4-I41T transgenic mice
To investigate the in vivo function of the mutant protein, we
generated a transgene construct containing the mouse Fig4-I41T
cDNA under the direction of the ubiquitously expressed chicken b-
actin promoter (Figure 3A). Expression of Fig4-I41T on a wildtype
background did not cause any visible abnormality in two independent
transgenic lines, which exhibited normal fertility and life span. The
transgene copy-number was measured by analysis of genomic DNA
by qPCR and demonstrated a transgene copy number of 4 copies in
line Tg705 and 2 copies in line Tg721 (Figure S3).
Quantitation of transgene transcript
Brain RNA was prepared from mice carrying the transgene on a
wildtype genetic background. qRT-PCR reactions were carried out
withTaqman primers in exon 3 and 4 and the product was detected
with a probe spanning the junction between exon 3 and exon 4.
Both endogenous transcripts and transgene-derived transcripts are
detected by this assay. The abundance of Fig4 transcripts was
compared withTata binding protein (Tbp) transcripts as an internal
control (see Materials and Methods). The ratio of Fig4 transcripts to
Author Summary
Charcot-Marie-Tooth disease type 4J is a severe neurolog-
ical disorder with childhood or adult onset and progres-
sion to loss of mobility and death. Patients inherit a
mutation that changes amino acid residue 41 of the FIG4
protein from isoleucine to threonine. We report that this
mutation destabilizes the FIG4 protein by blocking its
interaction with a stabilizing protein partner. We devel-
oped a mouse model of CMT4J and found that a low level
of expression of the mutant protein, 10% of wildtype level,
is sufficient to prevent lethality. This work provides the
scientific basis for development of a directed treatment for
this rare, lethal disorder.
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+/+,Tg705 brain was 36 higher than in
nontransgenic Fig4
+/+ mice (Figure 3B). Subtracting the 16
contribution from the endogenous Fig4 alleles, the contribution of
the 705 transgene is 26the level of endogenous expression. In the
brain of the higher expressing line Tg721, Fig4 transcript was 66
higher than in Fig4
+/+ mice, indicating that the transgene transcript
is expressed at 56endogenous expression (Figure 3B).
Low level of FIG4-I41T protein in transgenic lines on the
Fig4 null background
In order to generate a model of CMT4J expressing I41T in the
absence of wildtype Fig4 protein, the FIG4-I41T transgenic mice
were crossed with heterozygous mice carrying the Fig4 null (plt)
allele. Fig4-null mice carrying the I41T transgene were generated
in the expected Mendelian proportions from standard two-
generation crosses with both transgenic lines. When extracts from
brain and kidney of Fig4
2/2,Tg705 and Fig4
2/2,Tg721 mice
were examined by Western blotting, the abundance of FIG4-I41T
protein was substantially lower than in wildtype tissues (Figure 3C,
3D). With longer exposure, a low level of FIG4-I41T protein could
be detected in the Tg705 line, and a higher level in the Tg721 line,
consistent with their relative transcript levels (Figure 3E). Com-
parison with a 1:10 dilution of wildtype brain indicated that the
level of FIG4-I41T protein in line Tg721 is approximately 10% of
Figure 1. Impaired interaction of FIG4-I41T mutant protein with VAC14 and reduced co-immunoprecipitation with FAB1. A) Directed
yeast two-hybrid interaction of wildtype and mutant yeast Fig4p with Vac14p. Selection for Leu and Trp prototrophy was carried out under less
stringent (23AT) or more stringent (+3AT) conditions. B) Co-immunoprecipitation of myc-tagged Fig4p and GFP (Venus) -tagged Vac14p from yeast
lysates. C) Co-immunoprecipitation of myc-tagged Fig4p and GFP-tagged Fab1p. D) Directed yeast two-hybrid interaction of human FIG4 and human
VAC14. AD, activation domain alone; BD, DNA binding domain alone. The numbers above the lanes in B and C were obtained by densitometry of
non-saturated images and represent the ratio of Fig4p:Vac14p and Fig4p:Fab1p; the ratio for mutant Fig4p was normalized to the wildtype ratio.
doi:10.1371/journal.pgen.1002104.g001
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confirmed with a second antibody, a rabbit polyclonal antibody
generated to the same C-terminal antigen (Figure S4).
The abundance of VAC14 protein is normal in transgenic and
Fig4 null mice (Figure 3G, 3H). Thus low VAC14 protein is not
responsible for the low level of FIG4-I41T protein in the
transgenic lines. The data are consistent with the evidence above
from VAC14 null mice, and indicate that the FIG4-I41T protein is
destabilized in vivo by its reduced affinity for VAC14.
Dose-dependent survival in the I41T transgenic lines
Inheritance of the low expressing transgene Tg705 increased
survival ofFig4 nullmicefrom1–2monthsto3–6months(Figure 4).
These mice provide a model of human CMT4J, as described below.
In the high-expressing Tg721 line, lethality was completely
corrected (Figure 4). The oldest cohort of Fig4
2/2,Tg721 mice
have survived more than 28 months with no visible abnormalities.
The data demonstrate that a relatively low level of Fig4-I41T
protein can rescue the lethality of Fig4 null mice.
Rescue of neurodegeneration by the Fig4-I41T transgene
Fig4 null mice exhibit a reproducible pattern of spongiform
degeneration in the brain and extensive loss of neurons from
peripheral ganglia (Figure 5, top panel). Neurons in layers 4 and 5
of the cortex, the deep cerebellar nuclei, and the dorsal root
ganglia (DRG), are severely affected, with accumulation of
vacuoles that fill the cytoplasm [1]. In null mice carrying the
Tg721 transgene, these abnormalities are almost completely
eliminated. Spongiform degeneration of the brain is minimal
and DRG neurons are intact at P90 (Figure 5). In line Tg705, an
intermediate level of degeneration is visible at P90. In both
transgenic lines degeneration of the cerebellar nuclei is visible,
indicating that this region is extremely sensitive to PI(3,5)P2 levels
(Figure S5). Overall, neurodegeneration is rescued in a dose-
dependent manner.
Enlarged lateral ventricles and hydrocephalus are seen in both
transgenic lines (Figure 5, left panels). High pressure hydrocephalus
is indicated by the compression of the cerebellum and hippocampus
observed in all of the Fig4
2/2,Tg705 mice near the end of their
lifespan (Figure 5, bottom panel). This is also indicated by the
domed appearance of the head and the expulsion of cerebrospinal
fluid during dissection. The hydrocephalus in these mice is very
similar to that in the L156R (ingls) mutant of Vac14 [3].
Rescue of astrocytosis and autophagy in transgenic mice
Spongiform neurodegeneration in Fig4 null brain is accompa-
nied by accumulation of p62 and other autophagy intermediates,
predominantly in activated astrocytes [11]. In brain from
transgenic mice, there is an intermediate level of accumulation
of the autophagy markers p62 and LAMP-2 (Figure 6A).
Accumulation of the astrocyte protein GFAP is also corrected in
a dose-dependent manner (Figure 6A). Reduction of astrocytosis in
Tg721 mice is indicated by the decreased number of GFAP
positive cells (Figure 6B). Accumulated p62 and lysosomal
membrane protein LAMP-2 are localized in astrocytes of the
trangenic mice (Figure 6B), as previously shown in null mice [1].
In the high expressing Tg721 line, astrocytosis and GFAP
accumulation are almost completely corrected (Figure 6B).
Sciatic nerve myelination is rescued in transgenic mice
The defective myelination of peripheral nerves characteristic of
Charcot-Marie-Tooth disease is also seen in Fig4 null mice ([1]
and Figure 7A, top panel, arrows). In the two transgenic lines,
sciatic nerve myelination was comparable to wildtype (Figure 7A).
To quantitate axonal myelination we calculated the g-ratio, the
inner axon diameter divided by the diameter of the nerve fiber
(Figure 7B). At postnatal day 21, the g-ratio of 0.5 for wildtype
sciatic nerve is increased to 0.7 for Fig4 null sciatic nerve by the
thinning of the myelin sheath. In the transgenic mice the g-values
were restored to wildtype (Figure 7B).
Slowed nerve conduction secondary to defective myelination is
another characteristic of Charcot-Marie-Tooth disease that is
reproduced in Fig4 null mice [1]. In sciatic nerve of null mice at 1
month of age, the conduction velocity was 50% of the wildtype
value [1]. In contrast, conduction velocities in sciatic and sural
nerves from the two transgenic lines, measured at 4 months and 14
months of age, varied between 65% and 80% of wildtype
(Figure 7C, 7D), demonstrating partial rescue of the defect. The
amplitude of the compound action potential in sciatic nerve was
was also restored in the transgenic mice (data not shown).
Rescue of coat color in transgenic mice
Fig4-null mice have diluted pigmentation due to reduced
numbers of melanosomes in the mature hair follicle and clumping
of melanosomes within the hair shaft [1]. Pigmentation is partially
rescued in the higher expressing line Tg721, but not in line Tg705
(Figure S6). In view of the role of Fig4 in autophagy, it is interesting
that autophagy components may play a role in melanosome
biogenesis [16].
Expression of FIG4-I41T in patient fibroblasts
In order to determine whether the low abundance of the FIG4-
I41T protein in transgenic mice was representative of patient
tissues, we examined fibroblasts from a CMT4J patient who is a
Figure 2. Low level of wildtype FIG4 protein in Vac14 null mice. A) Absence of VAC14 protein in Vac14 null mouse. Protein extracts from
wildtype and Vac14 null P0 mice were probed with polyclonal antibody to VAC14 as described [9]. B) Absence of FIG4 protein in Vac14 null mouse.
The same extracts were probed with monoclonal antibody to FIG4. C, D) RT-PCR of RNA from Vac14 null mice with forward primer in Fig4 exon 3 and
reverse primer in exon 4 detects a normal level of Fig4 transcripts. DCT,C T for Fig4 minus CT for Tbp.
doi:10.1371/journal.pgen.1002104.g002
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R183X in exon 6 [2]. Exon 2 was amplified from patient and
control fibroblast RNA (Figure 8A). The sequence of the control
RNA contains a T nucleotide at position 122, encoding the
wildtype isoleucine allele. The patient RNA contains a C
nucleotide encoding threonine (Figure 8B). The absence of the
wildtype nucleotide in patient RNA indicates that the R183X
transcript is not stably expressed, probably due to degradation by
nonsense-mediated decay [17], consistent with its location at a
distance from the C-terminal exon 23.
Western blot analysis of fibroblast extracts demonstrated that
FIG4-I41T protein in patient fibroblasts is dramatically reduced in
comparison with wildtype (Figure 8C). The very low abundance of
FIG4-I41T protein, well below the expected 50% of normal,
indicates that the mutant protein is unstable in patient tissues, as it
is in the transgenic mice.
Stabilization of FIG4 by co-transfection of VAC14 in
HEK293 cells
The level of endogenous FIG4 in HEK293 cells was increased
by transfection of VAC14 (Figure 8D, lane 1 and 2). The level of
tranfected wildtype mouse FIG4 in HEK cells was also increased
by co-transfection of VAC14 (Figure 8D, lane 3 and 4). The
abundance of FIG4-I41T after transfection was much lower than
for the wildtype protein, and the effect of co-transfected VAC14
was much smaller (Figure 8D, lane 5 and 6). These experiments
Figure 3. Structure and expression of the Fig4-I41T transgene. A) Structure of the Fig4-I41T transgene containing the mouse Fig4 cDNA
downstream of the ubiquitously active chicken b-actin promoter. B) Quantitation of transgene mRNA by qRT-PCR using RNA from Fig4
+/+ wildtype
mice with the indicated transgene. RNA was isolated from brain at P28. The ratio of Fig4 transcript to Tbp (Tata binding protein) transcript is
calculated as described in Methods. C) Western blots of brain and D) kidney extracts from Tg705 and Tg721 transgenic lines stained with the
monoclonal anti-FIG4 antibody and compared with tissues from wildtype and Fig4 null mice. 100 ug of protein, 3 min film exposure. E) FIG4-I41T
protein can be detected in 100 ug of brain extract from transgenic lines after film exposure for 30 min. F) FIG4-I41T in 100 ug of brain protein from
Tg721 line is comparable to FIG4 in 10 ug of wildtype brain. G, H) VAC14 protein is present in brain from transgenic mice and Fig4
2/2 null mice.
doi:10.1371/journal.pgen.1002104.g003
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of VAC14 in cultured cells, and that mutant FIG4-I41T is less
effectively stabilized.
Effect of proteasome inhibition on FIG4-I41T
The level of FIG4 protein in primary fibroblasts from Tg721
transgenic mice is lower than in fibroblasts from wildtype mice
(Figure 8D), but is sufficient to prevent vacuolization (data not
shown). It was recently reported that the proteasome inhibitor
MG-132 increases the level of endogenous FIG4 protein in COS7
cells, indicating that there is turnover of FIG4 in the proteasome
[14]. To determine whether the mutant FIG4-I41T protein could
be stabilized, we cultured primary fibroblasts for 8 hrs with 10 uM
MG-132. The level of FIG4-I41T protein was significantly
increased by this treatment in fibroblasts from Tg721 transgenic
mice (Figure 8E). In control fibroblasts the level of wildtype FIG4
was also increased by culture with MG-132 (Figure 8F). The MW
of protein produced in the presence of MG-132 was higher than in
untreated cells (Figure 8E, 8F). Since MG-132 does not prevent
ubiquitination of substrates, the higher MW may be a conse-
quence of ubiquitination of the FIG4 protein.
Discussion
We have demonstrated that the FIG4-I41T protein is unstable
in vivo in cultured cells and in transgenic mice, and that the amount
of protein in cells from CMT4J patients is extremely low. FIG4
protein expression equivalent to 10% of wildtype levels is sufficient
to prevent neurodegeneration and completely rescue lethality in
transgenic line Tg721. In contrast, transgenic line Tg705, with
lower expression of FIG4-I41T, provides an animal model of the
human disorder with neurodegeneration. These key observations
suggest that increasing the expression of the FIG4-I41T allele in
CMT4J patients, or stabilizing the protein, would be therapeutic.
The low level of FIG4 protein in rescued mice and in patient
fibroblasts appears to be a consequence of the direct effect of the
I41T mutation on interaction with the scaffold protein VAC14. In
yeast the co-localization of Fig4p, Fab1p and Vac14p on the
vacuolar membrane requires the presence of all three proteins,
and loss of one protein prevents localization of the other two [3–5].
Similarly, in mammalian cells expressing an shRNA to downreg-
ulate Vac14 expression, a small reduction in endogenous FIG4
protein was reported [14].
We confirmed the importance of the FIG4-VAC14 interaction for
stability of wildtype FIG4 with the demonstration that FIG4 protein is
drastically reduced in mice homozygous for a null allele of VAC14.
This experiment clearly demonstrates the dependence of wildtype
FIG4 protein on VAC14 for in vivo stability. Because of its reduced
affinity for VAC14, FIG4-I41T is a hypomorphic allele encoding an
unstable protein, resulting in a very low steady-state level of protein in
vivo. The VAC14 protein is composed of heat-repeat domains [3] and
is thought to function as a scaffold for the PI(3,5)P2 biosynthetic
complex. In another example of the importance of interactions
between proteins in this complex, the missense mutation of Vac14 in
the ingls mouse which reduces the affinity of VAC14 for FAB1 and
results in a neurodegenerative disease that closely resembles the Fig4
null mice [3]. In the reciprocal experiment, VAC14 protein was not
reduced in Fig4 nullmice, demonstrating the greater intrinsic stability
of the mammalian scaffold protein, and/or its stabilization by
interaction with other components of the complex.
This model of pathogenesis is consistent with the structure of the
FIG4 protein, which was predicted by superimposition with the
crystal structure of Sac1p, a closely related lipid phosphatase [18].
Figure 4. Rescue of juvenile lethality by expression of the Fig4-I41T transgene. Kaplan-Meijer survival curves for Fig4 null mice carrying
Tg705 (n=17), Tg721 (n=21) transgenes or lacking the transgene (n=28). Transgene expression is indicated relative to wildtype expression.
doi:10.1371/journal.pgen.1002104.g004
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domain, in a hydrophobic pocket between two b-sheets (Figure 9).
The mutation was predicted to affect protein-protein interaction by
destabilizing the SacN domain [18], consistent with our observa-
tions. The I41T mutation is located at a distance from the catalytic
domain, and appears not to affect the enzymatic activity [14].
Based on our observations, increased expression or stabilization
of the FIG4-I41T protein in patients with CMT4J should be
therapeutic and could achieve complete rescue of this progressive
neurodegenerative disorder. Inhibition of proteasome degradation
with MG132 resulted in increased levels of FIG4-I41T protein in
cultured fibroblasts. This non-specific agent increased the
abundance of approximately 200 proteins in cultured fibroblasts
[19]. The proteasome inhibitor Velcade (bortezemib) has been
approved for treatment of multiple myeloma, and the widely used
drug disulfiram (Antabuse) was recently shown to have activity as a
proteasome inhibitor [20]. Pharmacological interventions like
these might increase FIG4 concentration to a level sufficient to
protect against loss of motor function in CMT4J patients with
genotype FIG4
I41T/2. Histone deacetylase inhibitors such as
sodium butyrate and tricostatin A that increase the expression of
other neurological disease genes such as SMN should also be
evaluated in CMT4J fibroblasts.
T h ec o r r e l a t e ds t e p w i s er e s c u eo fa utophagy, gliosis, neurodegen-
eration and lethality in the two transgenic lines supports our proposed
model of pathogenesis in which accumulation of autophagy
intermediates leads to neuronal damage and then to gliosis, neural
cell death and lethality [11,12]. PI(3,5)P2 appears to be required at a
step subsequent to the formation of the autolysosome [11], and may
be involved in the regeneration of lysosomes from autolysosomes [21].
A newly recognized function of PI(3,5)P2 is activation of the lysosomal
calcium channel TRPML1, which is mutated in the neurodegener-
ative disorder mucolipidosis type IV [22]. Transfection of TRPML1
into Vac14 null fibroblasts rescued the vacuolization caused by
deficiency of PI(3,5)P2 [22]. Increased lysosomal ion concentrations
resulting from PI(3,5)P2 deficiency in FIG4 mutant cells could
contribute to vacuolization via osmotic retention of water. Low
molecular weight activators of TRPML1 are under development and
might provide another route to treatment of PI(3,5)P2 deficiency.
The response of various tissues to rescue of FIG4 deficiency in
transgenic mice is summarized in Table 1. The dramatically
improved survival of cortical and dorsal root neurons, and the
complete rescue of lethality, indicate that a small amount of I41T
protein is sufficient for normal function in most affected cells.
Fifteen CMT4J pedigrees segregating the I41T allele have been
identified to date ([1,2] Nicholson et al, unpublished data). In all of
Figure 5. Spongiform degeneration of brain and DRG is rescued by the Fig4-I41T transgene. Top: Sagittal brain section, cortex, and DRG
from Fig4 null mice demonstrating enlarged ventricle and spongiform degeneration (scale bar=200 mm). Middle panels: Partial rescue of Fig4 null
mice carrying Tg705 (26expression) and Tg721 (56expression). Bottom panel: Sagittal sections of brain from wildtype mice (left) and transgenic
mice in the final stage of disease progression. Both transgenes provide protection from neurodegeneration, with greater protection in the higher
expressing line.
doi:10.1371/journal.pgen.1002104.g005
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chromosome haplotype, indicating inheritance of a shared founder
mutation. In spite of their shared FIG4
I41T/2 genotype, the clinical
course in CMT4J patients is highly variable. Age of onset ranges
from an early childhood form with developmental delays that
resembles Dejerine-Sotas syndrome to an adult onset form with
rapid progression that may be triggered by trauma [1,2].
Background genetic variation affecting the level of expression of
VAC14orotherproteinsinthePI(3,5)P2biosyntheticcomplexcould
contribute to the clinical differences in patients with identical FIG4
genotype. The Tg705 model of CMT4J, which survives for 3 to 6
months and then develops severe disease, will be useful for testing
therapies designed to increase the in vivo level of FIG4-I41T protein.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the University Committee on the Use
and Care of Animals (UCUCA) of the University of Michigan
(Protocol No. 08629).
Fig4 null mice
The Fig4 null mutant ‘‘pale tremor’’ (plt) arose spontaneously
in a mixed strain background that included C57BL/6J, C3H,
129 and SJL. This stock was crossed for one generation to
strain C57BL/6J. Heterozygous plt/+ offspring were crossed to
strain CAST/Ei to produce an F2 generation for genetic
mapping [1]. plt/+ F2 mice were intercrossed to initiate a
recombinant inbred line that is maintained by brother6sister
breeding and is now at generation F12. The genetic
background of this line, designated CB.plt, is approximately
50% CAST/Ei and 25% C57BL/6J, with smaller contributions
from strains C3H, 129 and SJL.
Transgenic mice
The mouse Fig4 transcript was amplified from brain RNA
isolated from strain C57BL/6J using two primers containing
SphI sites: F, ACG CAT GCT ATG CTA TGT GTC TGG
TGT GCT GGA GGT CTG and R, TCGC A TG C AG T C
CTT TAC CCA TGA GCT GCA TC. The product was
digested with SphI and subcloned into the corresponding site of
the vector pCAG3z [23,24]. The I41T mutation was incorpo-
rated into the Fig4 cDNA clone by site-directed mutagenesis
and the construct was completely sequenced. Plasmid DNA was
isolated with the Qiagen MaxiPrep Kit and digested to generate
a linear fragment containing the cDNA sequence with the
promoter and polyadenylation site. Transgenic mice carrying
the Fig4-I41T cDNA construct were generated by microinjec-
tion of (C57BL/6J X SJL)F2 mouse oocytes at the Transgenic
Animal Model Core at the University of Michigan (www.med.
umich.edu/tamc). Transgenes were maintained in heterozygous
Figure 6. Dose-dependent rescue of the autophagy defect in brain of transgenic mice. A) Western blots of accumulated autophagy
markers LAMP2 and p62 and astrocyte marker GFAP in brain homogenates from wildtype, transgenic and Fig4 null mice at P28; 30 ug protein per
lane. B) Accumulation of of LAMP2 and p62 immunofluorescence in GFAP-positive astrocytes in the cortex of transgenic lines at P28. Astrocyte
abundance is dramatically increased in Fig4 null mice (Scale bars=200 mm).
doi:10.1371/journal.pgen.1002104.g006
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between multi-copy inserts.
Yeast functional tests
The yeast two-hybrid test and immunoprecipitation analysis
were carried out as previously described [3]. Human and yeast
VAC14 were subcloned into the ClaI–BglII and XmaI–SalI sites of
pGAD, respectively. Human and yeast wild type and mutant FIG4
were subcloned into the XmaI–SalI and BamHI–PstI sites of pGBD,
respectively. pGAD and pGBD plasmids were cotransformed into
the yeast strain PJ69-4A. Transformants were initially plated onto
SC-LEU-TRP media for plasmid selection and replica-plated onto
selective plates with SC-LEU-TRP-ADE-HIS+3AT media or SC-
LEU-TRP-ADE-HIS media and grown at 24uC for 4 to 14 days
for colony formation. The yeast strain PJ69-4A and the pGAD
and pGBD vectors have been described [25]. The Venus-
derivative of GFP was previously described [15]. Selective media
contained 3-amino-1,2,4-triazole (3AT), an inhibitor of His3p.
Immunofluorescence and Western blots
Immunocytochemistry of p62, LAMP2 and GFAP on fresh
frozen cryosections of mouse brain and Western blotting of brain
extracts were carried out as previously described [11]. For
immunoblotting of FIG4, tissues were homogenized in 0.25 M
sucrose, 0.05 M Tris, pH 7.5 and the 21,0006g soluble fraction
was analyzed. Immunofluorescence images were captured on an
Olympus BX51 microscope equipped with epifluorescence and
processed and merged with Adobe Photoshop software.
FIG4 antibodies
A rabbit polyclonal antiserum and a mouse monoclonal
antibody were generated to a C-terminal fragment of FIG4
containing the final 220 amino acids, residues 688 to 907, which is
encoded by exons 18 to 23. A 660 bp cDNA fragment was
amplified from a full length Fig4 cDNA derived from strain
C57BL/6J and cloned into the XhoI and EcoRI sites of the
expression vector pRSETA (Invitrogen Corporation, Calrsbad,
Figure 7. Rescue of peripheral nerve myelination and nerve conduction velocity in transgenic Tg705 and Tg721 lines. A) Transmission
electron microscopy of cross-sections of sciatic nerve from Fig4 mutant and wildtype mice at P21. Arrows in the top panel indicate thinly myelinated
axons in Fig4
2/2 mice. B) Quantitation of g-ratio in sciatic nerve; higher g-ratio indicates a thinner myelin sheath. Fig4
2/2 (n=89 axons); Fig4
2/2,
Tg705 (n=181 axons); Fig4
2/2, Tg721 (n=152 axons); Fig4
+/+ (n=109 axons). Scale bar: 5 mm. Error bars, SEM. P,0.05 for Fig4
2/2 versus WT, Fig4
2/2
versus Tg705, and Fig4
2/2 versus Tg712 (Student’s t-test). C, D) Nerve conduction velocity was measured in sciatic nerve and sural nerve from 4
month old unaffected Fig4
2/2,Tg705 mice and 14 month old unaffected Fig4
2/2,Tg721 mice (mean +/2 SEM).
doi:10.1371/journal.pgen.1002104.g007
Pathogenic Mechanism of Human FIG4 Mutation
PLoS Genetics | www.plosgenetics.org 9 June 2011 | Volume 7 | Issue 6 | e1002104CA, USA), adding a polyhistidine tag (66His) to the N-terminus.
Recombinant protein was expressed in E. coli and purified from
inclusion bodies using Novagen BugBuster Protein Extraction
Reagent (EMD Chemicals, Gibbstown, NJ, USA). Rabbit
polyclonal antiserum to the purified protein was generated and
affinity-purified by Pocono Rabbit Farm and Laboratory, Inc.
(Canadensis, PA). The purified polyclonal antiserum was used at
1:50 dilution for western blots. The monoclonal antibody was
generated using the same protein fragment at the UC Davis/NIH
NeuroMab Facility (Clone N202/7). The monoclonal was purified
from cell culture and used at 1:200 for western blots. A broad
crossreacting band of 50 to 55 kDa is ocassionally observed on
Western blots of control and mutant tissues but there is no
consistent association with genotype.
Histology
Brain and spinal cord were fixed for 24 hours at 4uCi n
phosphate buffered 10% formalin and then in 70% ethanol for an
additional 24 hours at 4uC. Paraffin embedding, decalcification of
spine, and H&E staining were carried out at Histoserv Inc
(Maryland). Images were obtained with an Olympus BX51
microscope and DP50 camera. Image capture settings were
identical for sections from 2/2 and 2/2,Tg705 mice that
exhibited immunostaining for autophagy markers. To detect the
outlines of brain sections from 2/2,Tg721 and +/+ mice that
lacked immunostaining, a longer image capture time was used.
qRT-PCR of Fig4 transcripts
Five ug aliquots of total RNA from whole brain was treated with
DNAse I (Invtrogen) and cDNA was prepared using the SuperScript
First Strand Synthesis System for RT-PCR (Invitrogen). The Fig4
transcript was quantitated using TaqMan gene expression probe
Mm00506074_m1 (ABI) which spans the junction between exon 3
and exon 4. As an internal control, the TATA binding protein (Tbp)
transcript was quantitated using TaqMan probe Mm00446971_m1.
Fluorescence was measured on a Step One Real Time PCR System
(ABI) at the Microarray Core at the University of Michigan. A linear
relationship between copy number and CT, the threshold cycle for
detection of fluorescence, was observed (Figure S3). The mean CT
value was determined from quadruplicate assays of each sample.
The value of DCT was calculated by subtracting the CT for Tbp from
the CT for Fig4. The ratio of Fig4 transcripts to Tbp transcripts was
calculated as 2
2DCT.
Transgene copy number determination by qPCR
Transgene copy number was determined using the TaqMan
probe described above. A standard curve was generated using
Figure 8. FIG4 transcript and protein in CMT4J patient fibroblasts. A) RT-PCR products containing exon 2 were amplified from total fibroblast
RNA with a forward primer in exon 1 and reverse primer in exon 3. B) Sequence of the RT-PCR product demonstrating nucleotide c.122T (isoleucine)
in the control RNA and nucleotide c.122C (threonine) in the patient RNA. C) Western blot of 60 ug of protein from patient and control fibroblasts. D)
HEK293T cells transfected with wildtype mouse FIG4 cDNA transgene (Figure 3) or the corresponding I41T construct. Co-transfection of VAC14
stabilizes endogenous and transfected FIG4 proteins. E) The low level of FIG4 in primary fibroblasts from Tg721 transgenic mice is increased by
culture for 8 hours in the presence of 10 uM concentration of the proteasome inhibitor MG-132. F) Incubation of wildtype fibroblasts with MG-132
increases the level of FIG4 protein.
doi:10.1371/journal.pgen.1002104.g008
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number standards of 0, 0.5, 1, 2, 4, 8, and 16 copies per haploid
genome using 2.83 pg/ug for one haploid copy equivalent for this
3 kb transgene. Genomic DNA (50 ng) from Tg705/+ mice,
Tg721/+ mice, and standards were assayed in quadruplicate.
The Taqman probe includes the junction between exon 3 and
exon 4, which are separated by 4 kb in genomic DNA. No
fluorescent signal was obtained from 8 replicates of wildtype
genomic DNA. R
2 for the standard curve was 0.999. Observed
copy numbers for both transgenic lines are within the linear
range of the assay.
Primary fibroblasts and HEK293 cells
HEK293 cells (passage 15) were maintained in DMEM/F-12
supplemented with 10% fetal bovine serum, penicillin, streptomy-
cin and amphotericin. Subconfluent cells in 10 cm dishes were
transfected with 6 ug plasmid DNA and 18 uL FuGene (Roche)
for 24 hours in complete culture media. Cells were lysed in RIPA
buffer and lysates were spun at 15,0006 g for 10 minutes.
Supernatant protein was quantitated using the BCA kit (Pierce).
Mouse fibroblasts were isolated from P0 mouse tail biopsy by
digestion with collagenase type 2 (Worthington labs) and cultured
in RPMI 1640 supplemented with 15% fetal bovine serum and
Figure 9. Location of the FIG4-I41T mutation and effect on protein interaction. A) Predicted structure for FIG4 phosphatase based on
protein coordinates of yeast Sac1 phosphatase(18). The isoleucine residue mutated in CMT4J (red) is located near the surface of the N-terminal
domain (blue) that is predicted to function in protein-protein interaction [18]. The catalytic domain (yellow) contains the active site (green). Image
courtesy of Yuxin Mao. B) Predicted orientation of the FIG4 protein in the PI(3,5)P2 biosynthetic complex [3]. As shown in this paper, the I41T mutation
of FIG4 (red) reduces interaction with both FAB1 and VAC14.
doi:10.1371/journal.pgen.1002104.g009
Table 1. Rescue of various phenotypes of the Fig4 null mice by the Tg705 and Tg721 I41T transgenes.
Fig4 genotype 2/2 2/2, Tg705 2/2, Tg721 +/+
brain transcript 0 26 56 16
FIG4 protein none I41T I41T wildtype
survival 1–2 months 3–6 months .2y e a r s .2 years
degeneration of cerebral cortex extensive intermediate none none
degeneration of DRG extensive intermediate none none
degeneration of deep cerebellar nuclei extensive intermediate intermediate none
autophagic inclusion bodies extensive intermediate few none
hydrocephalus present present present rare
coat color pale pale intermediate wildtype
nerve conduction velocity reduced intermediate intermediate normal.
sciatic nerve myelination defective normal normal normal
doi:10.1371/journal.pgen.1002104.t001
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ments were carried out at passage 3 to 5. Treatment with 10 uM
MG-132 (Sigma) was carried out in complete media for 8 hours.
Primary cultured fibroblasts from CMT4J patient 2 were
previously described [8]; passage 4 cells were kindly provided by
Dr. Jun Li, Department of Neurology, Vanderbilt University.
Nerve conduction velocity
Nerve conduction velocity (NCV) was measured as previously
described [26]. Mice were anesthetized and maintained at a 34uC
core temperature with a heating lamp. Sural sensory NCV was
determined by recording at the dorsum of the foot and
antidromically stimulating with supramaximal stimulation at the
ankle. NCV was calculated by dividing the distance by the take-off
latency of the sensory nerve action potential. Sciatic-tibial motor
NCV was determined by recording at the dorsum of the foot and
orthodromically stimulating with supramaximal stimulation first at
theankle,then atthesciaticnotch. Latencies were measuredineach
case from the initial onset of the compound muscle action potential.
The sciatic-tibial motor NCV was calculated by subtracting the
measured ankle distance from the measured notch distance. The
resultant distance was then divided by the difference in the ankle
and notch latencies for a final nerve conduction velocity.
Electron microscopy of sciatic nerve axons
Mice were anesthetized with ketamine and xylazine and
perfused transcardially with 3% paraformaldehyde (Electron
Microscopy Sciences) and 2.5% glutaraldehyde (Ted Pella, Inc.).
Sciatic nerves were dissected and post-fixed for several hours in
perfusion solution at 4uC. Tissues were incubated in a 1% solution
of OsO4 and embedded in epoxy resin. Ultrathin (75 nm) sections
were cut and visualized with a Philips CM-100 TEM. Images were
analyzed at 2600-fold magnification using Image-J software for
quantification of g-ratio (defined as the diameter of an axon within
its myelin sheath divided by the diameter of the axon outside of its
myelin sheath). Two measurements were made per axon in order
to account for elongated or irregular shape, and the mean was
used. Only myelinated axons were used in for the calculation of g-
ratio. Data were compared using Microsoft Excel.
Accession numbers
Accession numbers for the genes referred to in this paper are:
human FIG4 (Entrez Gene ID 9896), mouse Fig4 (Entrez Gene ID
103199), yeast Fig4p (Entrez Gene ID 855392), mouse Vac14
(Entrez Gene ID 234729), yeast Vac14p (Entrez Gene ID 851102),
mouse Fab1/PIKfyve (Entrez Gene ID 18711), yeast Fab1p
(Entrez Gene ID 850574).
Supporting Information
Figure S1 Specificity of the monoclonal anti-FIG4 antibody.
A)The indicated 220 amino acid C-terminal fragment of FIG4
(immunogen) was isolated after bacterial expression and provided
to the UC Davis/NIH NeuroMab Facility for generation of the
monoclonal antibody. B) Antibody from NeuroMab (Clone N202/
7) was diluted 1:200 for immunostaining of Western blots
containing 100 ug of protein from brain homogenate. Equal
protein transfer to the filter for wildtype and Fig4 null brain is
demonstrated by Ponceau Red staining.
(TIF)
Figure S2 Low level of wildtype FIG4 protein in cultured fibroblasts
from Vac14 null mice. The Western blot was probed with the
monoclonal anti-FIG4 antibody. FIG4 protein could not be detected
in P0 tissue, as shown in the text; the level of FIG4 in cultured
fibroblasts is just above the detectable level. Each lane contained 60 ug
of protein. Comparable loading of the two lanes is demonstrated by
the Ponceau-stained gel below.The low abundance of FIG4 protein in
the Vac14 null mouse demonstrates the importance of the VAC14
scaffold protein for stabilization of wildtype FIG4 in vivo.
(TIF)
Figure S3 Transgene copy number in two lines of Fig4-I41T
transgenic mice. Copy number was assessed by quantitative PCR of
genomic DNA. Standards were prepared by addition of varying
amounts of transgene plasmid DNA to wildtype genomic DNA. The
linear relationship between copy number and the threshold cycle
number CTis demonstratedat the right. The PCRprimers are located
in exon 3 and exon 4 and do not amplify the endogenous Fig4 gene
because the exons are separated by a 4 kb intron in genomic DNA.
(TIF)
Figure S4 Western blot with polyclonal rabbit anti-FIG4
demonstrates low abundance of FIG4-I41T protein in transgenic
lines. The polyclonal antibody was generated against the
bacterially-expressed 220 amino acid C-terminal protein fragment
used to generate the monoclonal antibody (Figure S1). Each lane
contains 100 ug of brain soluble protein.
(TIF)
Figure S5 Incomplete rescue of cerebellar nuclei in Fig4-I41T
transgenic mice. (Scale bar=500 mm).
(TIF)
Figure S6 Partial rescue of the pigmentation defect in transgenic
mice. The diluted pigmentation of congenic B6.Tg705 and
B6.Tg721 mice compared with wildtype black mice (+/+). The
(C57BL/6J X SJL)F2 transgenic founders were backcrossed to
strain C57BL/6J to generate the B6.Tg705 and B6.Tg721 lines.
Transgenic B6 mice at N6 were crossed with the congenic line
B6.plt (N10) to generate the null transgenic mice shown here.
(TIF)
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